Breast Cancer Trial
Testing the Ability to Decrease Chemotherapy in Patients with HER2-Positive Breast Cancer Who Have No Remaining Cancer at Surgery after Limited Pre-operative Chemotherapy and HER2-Targeted Therapy
Part 1 component of the CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer)
Physician and Research Staff Educational Material
This material is intended for promotional use among health care professionals and is NOT intended for use as patient educational material.
Information and Assistance from the National Cancer Institute
- Locations and other information
- Trained information specialists at the NCI are available to answer cancer-related questions from patients, family members or friends, health care providers, and researchers. Visit the NCI’s Cancer Information Service webpage for contact instructions, including telephone, live chat, email, and mail.
ClinicalTrials.gov ID: NCT04266249
Return to Home Page | Review Other Active Trials